Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-21-Speech-2-494"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20100921.18.2-494"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Mr President, first of all, I would like to start by thanking and congratulating the rapporteur, together with all the Members who have been involved in this process.
As we know, adverse drug reactions are the fifth most common cause of hospital deaths – it cannot be said too often – and a strong, transparent pharmacovigilance system is essential. We now have the opportunity to enhance the safety of those medicines that are already available by going beyond laboratory tests, which do not always catch problems before they arise.
If concrete examples were necessary to justify the importance of a new system, one need only look at what happened with the H1N1 influenza vaccine: the vaccine was rushed onto the market, but the side effects that were detected were not investigated with due care and are still delaying a full inquiry.
That is why we need to continue to improve these measures. This directive ensures that both healthcare professionals and patients will be more actively involved in identifying difficulties. Cooperation between countries and the Union may, in fact, be a plus-sum game."@en1
|
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples